Gm13718 inhibitors are a class of chemical compounds specifically developed to inhibit the activity of the Gm13718 protein, a protein whose precise biological role is still under investigation but is believed to be involved in key cellular functions such as signaling pathways and regulatory mechanisms. These inhibitors are typically small molecules that interact with the Gm13718 protein at specific sites, including the active site or other crucial functional domains. By binding to these sites, the inhibitors prevent Gm13718 from engaging in its normal interactions with substrates or other cellular components, effectively reducing or abolishing its activity. The binding of the inhibitors can result in the formation of a stable protein-inhibitor complex, which alters the conformation of Gm13718 and disrupts its function.
The development of Gm13718 inhibitors requires a thorough understanding of the protein's structure and the molecular interactions that govern its activity. Researchers employ a variety of techniques, including high-throughput screening, computational modeling, and structure-activity relationship (SAR) studies, to identify and optimize compounds that exhibit high affinity and specificity for Gm13718. The chemical structures of these inhibitors are designed to incorporate functional groups capable of forming strong and specific interactions with the protein. These interactions often include hydrogen bonds, hydrophobic interactions, and van der Waals forces, which help stabilize the inhibitor within the protein's binding pocket. Achieving high selectivity is a key objective in the design of Gm13718 inhibitors, ensuring that these compounds selectively target Gm13718 without affecting other proteins with similar structures or functions. This selectivity is essential for studying the specific role of Gm13718 in cellular processes, as it allows researchers to modulate its activity precisely and investigate its contributions to various biological pathways. The insights gained from such studies are valuable for furthering our understanding of the complex network of protein interactions within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $73.00 $246.00 | 7 | |
May interfere with vitamin K metabolism, potentially affecting blood clotting processes. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Might inhibit serotonin reuptake, potentially affecting mood and emotional responses. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Could inhibit proton pumps, potentially affecting gastric acid secretion. | ||||||
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $49.00 $91.00 | 21 | |
May inhibit angiotensin-converting enzyme, potentially affecting blood pressure regulation. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Could modulate estrogen receptor activity, potentially influencing cell growth in certain tissues. | ||||||
Cyclosporine | 79217-60-0 | sc-358111 sc-358111A | 100 mg 1 g | $195.00 $1012.00 | 2 | |
Might inhibit calcineurin, potentially affecting T-cell activation and immune response. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Could intercalate DNA, potentially affecting DNA synthesis and cell proliferation. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
May inhibit HMG-CoA reductase, potentially affecting cholesterol synthesis. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Could activate adrenergic receptors, potentially affecting fight-or-flight responses. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Might modulate intracellular signaling, potentially affecting mood and neurological function. | ||||||